• EN

Figure PPP-2. Indexed trends in EU potency/purity for major drug types, adjusting for population size, 2004-2009


1. The trends represent the available information on national potency / purity for each drug in the EU Member States and Norway, weighted by country population sizes to form an overall EU trend. All series indexed to a base of 100 in 2004.

2. Countries missing drug price information for two or more consecutive years are not included in the trend calculations: the trend for  amphetamine on nineteen countries (80 % of the EU population 15-64), cocaine on twenty-two countries (90 % of the EU population 15-64), ecstasy on fourteen countries (58 % of the EU population 15-64), herbal cannabis on fourteen countries (65 % of the EU population 15-64), and cannabis resin on fifteen countries (66 % of the EU population 15-64). Trends for other drugs are not available due to insufficient data.

3. Additionally, where 2009 data are missing (fifteen cases) 2008 prices are used; for missing 2004 data (fifty-five cases) 2005 prices are used; data missing for other years (twenty-three cases) have been interpolated from adjacent years.

Related links:

population 15-64 data: http://epp.eurostat.ec.europa.eu/

See also 'General notes for interpreting data' on the Explanatory notes and help page.


Potency / purity  data: Reitox National Focal Points

(see the help page for information about formats etc.)

About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU's decentralised agencies. Read more >>

Contact us

Praça Europa 1, Cais do Sodré
1249-289 Lisbon
Tel. (351) 211 21 02 00
Fax (351) 218 13 17 11

More contact options >>

Page last updated: Tuesday, 02 August 2011